S2 2.25 %
EPINEPHRINE RACEMIC : 2.25 % · DIN 00525103 · NEPHRON PHARMACEUTICALS CORPORATION
Health Canada status: CANCELLED POST MARKET
What is S2?
S2 2.25 % contains EPINEPHRINE RACEMIC : 2.25 %. It is listed in the Health Canada Drug Product Database under DIN 00525103, held by NEPHRON PHARMACEUTICALS CORPORATION, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as cancelled post market, status dated 20-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00525103 |
|---|---|
| Brand name | S2 |
| Generic / active ingredient | EPINEPHRINE RACEMIC : 2.25 % |
| Manufacturer | NEPHRON PHARMACEUTICALS CORPORATION |
| Strength | 2.25 % |
| Dosage form | SOLUTION |
| Route of administration | INHALATION |
| Schedule | Ethical |
| ATC code | R03AA01 EPINEPHRINE |
| AHFS class | 12:12.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 20-Jul-2018 |
| Original market date | 1998-10-02 00:00:00 |
Is EPINEPHRINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code R03AA01 EPINEPHRINE. 0 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRONKAID MISTOMETER AEM 0.5% | 0.5 % | METERED-DOSE AEROSOL | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02017555 |
| DYSNE INHAL | 3.5 % | SPRAY | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 00466417 |
| VAPONEFRIN | 2.25 % | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 01927582 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.